When XDx yesterday filed to raise up to $86.3 million in an IPO, the Brisbane, Calif., company joined just a handful of similar molecular-diagnostic companies to test the public markets. XDx ...

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company that discovers, develops and commercializes high value, non-invasive tests to monitor immune status in transplant ...

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, today announced the ...

XDx, a Brisbane, Calif. company that monitors the immune system with personalized medicine based on insights from the Human Genome Project, said it is raising up to $25 million more in cash. The news, ...

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire/ -- XDx, Inc., a molecular diagnostics company, announced today that it has completed a $20 million Series D private equity financing. Sprout Group led ...

BRISBANE, Calif.--(BUSINESS WIRE)-- XDx, Inc., a molecular diagnostics company that discovers, develops and commercializes high value, non-invasive tests to monitor immune status in transplant ...

A doctor threads a catheter through the jugular vein of a heart transplant recipient and manipulates it to the patient's heart to remove tissue samples to check for signs that the body's immune system ...

XDx Inc. has announced that it has signed an agreement with the University of Minnesota to exclusively license key intellectual property assets in the field of Systemic Lupus Erythematosus (SLE). The ...